Growth Metrics

Haemonetics (HAE) Depreciation & Amortization (CF) (2016 - 2025)

Haemonetics has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $27.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 5.65% year-over-year to $27.4 million; the TTM value through Dec 2025 reached $112.6 million, down 2.1%, while the annual FY2025 figure was $115.6 million, 18.9% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $27.4 million at Haemonetics, down from $28.3 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $29.2 million in Q3 2024 and troughed at $21.9 million in Q2 2021.
  • A 5-year average of $25.5 million and a median of $24.6 million in 2022 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 23.83% in 2021 and later increased 26.96% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $23.5 million in 2021, then rose by 0.15% to $23.6 million in 2022, then decreased by 0.17% to $23.5 million in 2023, then rose by 23.35% to $29.0 million in 2024, then decreased by 5.65% to $27.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for HAE at $27.4 million in Q4 2025, $28.3 million in Q3 2025, and $28.8 million in Q2 2025.